| 1 |
Shah DD, Dave BP, Patel PA, Chorawala MR, Patel VN, Shah PA, Patel MP. Revamping the innate or innate-like immune cell-based therapy for hepatocellular carcinoma: new mechanistic insights and advanced opportunities. Med Oncol 2023;40:84. [PMID: 36680649 DOI: 10.1007/s12032-023-01948-4] [Reference Citation Analysis]
|
| 2 |
Malaina I, Martínez L, Montoya JM, Alonso S, Boyano MD, Asumendi A, Izu R, Sanchez-Diez A, Cancho-Galan G, M de la Fuente I. A Universal Antigen-Ranking Method to Design Personalized Vaccines Targeting Neoantigens against Melanoma. Life (Basel) 2023;13. [PMID: 36676104 DOI: 10.3390/life13010155] [Reference Citation Analysis]
|
| 3 |
Noordam L, de Beijer MT, Mancham S, Vogler I, Boor PP, de Ruiter V, Luijten R, Ijzermans JN, Sahin U, Bruno MJ, Sprengers D, Buschow SI, Kwekkeboom J. Systemic T-cell and humoral responses against cancer testis antigens in hepatocellular carcinoma patients. OncoImmunology 2022;11:2131096. [DOI: 10.1080/2162402x.2022.2131096] [Reference Citation Analysis]
|
| 4 |
Dmitrieva MV, Baryshnikovа MA, Orlova OL, Kosorukov VS. Technological aspects of creating neopeptide vaccines. Rossijskij bioterapevtičeskij žurnal 2022;21:10-21. [DOI: 10.17650/1726-9784-2022-21-4-10-21] [Reference Citation Analysis]
|
| 5 |
Han H, Jin W, Li X. Mesenchymal stem cells-based therapy in liver diseases. Mol Biomed 2022;3:23. [DOI: 10.1186/s43556-022-00088-x] [Reference Citation Analysis]
|
| 6 |
Zhang CY, Liu S, Yang M. Regulatory T cells and their associated factors in hepatocellular carcinoma development and therapy. World J Gastroenterol 2022; 28(27): 3346-3358 [DOI: 10.3748/wjg.v28.i27.3346] [Reference Citation Analysis]
|
| 7 |
Repáraz D, Aparicio B, Llopiz D, Hervás-Stubbs S, Sarobe P. Therapeutic Vaccines against Hepatocellular Carcinoma in the Immune Checkpoint Inhibitor Era: Time for Neoantigens? Int J Mol Sci 2022;23:2022. [PMID: 35216137 DOI: 10.3390/ijms23042022] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
|
